On this page
SLC6A8
solute carrier family 6 member 8
SLC6A8 is located on the long (q) arm of chromosome X, at band Xq28. Arm ratio per GRCh38 - banding schematic.
Explore chromosome X in the library →Available at Jeen Health
Clinical tests that include this
Overview
SLC6A8 encodes the sodium- and chloride-dependent creatine transporter 1, a membrane protein that enables cells to acquire creatine from the bloodstream. Creatine serves a fundamental role in cellular energy metabolism by participating in the phosphocreatine system, which maintains ATP availability during periods of high energy demand. Because the gene resides on the X chromosome, males carrying pathogenic variants typically experience more severe manifestations than females, who may exhibit variable features depending on X-inactivation patterns.
The importance of functional creatine transport becomes particularly evident in tissues with high metabolic requirements. Brain tissue relies heavily on efficient energy provision for neurotransmission and cellular maintenance, whilst skeletal and cardiac muscle require rapid ATP regeneration during contraction. Disruption of creatine delivery to these tissues results in the clinical syndrome known as cerebral creatine deficiency, characterised by intellectual disability, speech delay, behavioural difficulties, and sometimes seizures or movement disorders.
What the gene does
The creatine transporter protein produced from SLC6A8 belongs to the solute carrier 6 family of membrane transport proteins. This transporter actively moves creatine molecules from the extracellular environment into the cytoplasm, coupling creatine uptake to the co-transport of sodium and chloride ions down their electrochemical gradients. This secondary active transport mechanism concentrates creatine within cells against its concentration gradient.
Once inside cells, creatine becomes phosphorylated by creatine kinase to form phosphocreatine, creating an energy buffer system. During periods when ATP consumption exceeds production, phosphocreatine donates its phosphate group to ADP, rapidly regenerating ATP without requiring oxygen. This buffering capacity proves essential in excitable tissues such as neurons and muscle fibres, where energy demand fluctuates rapidly.
The transporter exhibits particularly high expression in organs with substantial energy requirements. Brain tissue expresses significant amounts to support neuronal activity and synaptic transmission. Skeletal muscle and cardiac tissue similarly depend on efficient creatine uptake to maintain contractile function. Reduced transporter activity compromises the ability of these tissues to establish adequate phosphocreatine reserves, undermining their capacity to sustain normal metabolic activity.
Video: Genetics 101
Chromosome location
SLC6A8 is located on the long arm of the X chromosome at position Xq28, near the telomere. This chromosomal region contains numerous other genes, and the X-linked position explains the inheritance pattern observed in families affected by creatine transporter deficiency. Males, having only one X chromosome, express the phenotype when they inherit a pathogenic variant, whilst females with one altered copy may show variable features or remain asymptomatic depending on which X chromosome is preferentially inactivated in different tissues.
Protein structure
The SLC6A8 protein comprises 635 amino acids that form a membrane-spanning transporter with multiple transmembrane domains characteristic of the solute carrier 6 family. The N-terminal region, spanning approximately amino acids 1 to 28, is predicted to be disordered, likely serving a regulatory or flexible linker function before the structured transporter core begins. The transmembrane segments create a central substrate-binding pocket that coordinates creatine along with sodium and chloride ions during the transport cycle. Conformational changes within this architecture enable the protein to alternate between inward-facing and outward-facing states, facilitating substrate translocation across the lipid bilayer.
Key variants
More than 80 pathogenic variants in SLC6A8 have been documented in individuals with X-linked creatine deficiency. These variants include missense substitutions that impair substrate binding or ion coupling, nonsense mutations that truncate the protein prematurely, and deletions that disrupt the reading frame. Missense changes affecting transmembrane domains or residues critical for ion coordination tend to reduce transporter activity substantially. The severity of clinical manifestations often correlates with the degree of residual transporter function, though complete loss of activity typically results in the full syndrome presentation.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
Pathogenic variants in SLC6A8 cause cerebral creatine deficiency (SLC6A8), an X-linked recessive condition characterised by intellectual disability, delayed or absent speech development, behavioural problems, and sometimes seizures. Males with this condition generally exhibit moderate to severe cognitive impairment, whilst carrier females may show mild learning difficulties or remain unaffected. Neuroimaging studies often reveal reduced creatine levels in brain tissue, and biochemical testing demonstrates low or absent creatine in the brain despite normal levels in blood. The condition cannot be corrected by dietary creatine supplementation, as the underlying defect prevents cellular uptake regardless of extracellular creatine availability.
Inheritance pattern
Conditions caused by pathogenic SLC6A8 variants typically follow x-linked inheritance.
X-linked recessive: sons of a carrier mother have a 50% chance of being affected. Daughters have a 50% chance of being carriers.
UK clinical status
SLC6A8 appears on several NHS Genomic Medicine Service gene panels, reflecting its recognised role in paediatric neurodevelopmental and metabolic disorders. The gene holds green (diagnostic-grade) classification on the Intellectual Disability panel (R29), Early Onset or Syndromic Epilepsy panel (R59), and Childhood Onset Dystonia, Chorea or Related Movement Disorder panel (R57). It is also included in the Likely Inborn Error of Metabolism panel (R98) and the Developmental Disorders Genotype-to-Phenotype (DDG2P) database. These listings support the use of SLC6A8 analysis in clinical diagnostic pathways for children presenting with unexplained developmental delay, seizures, movement abnormalities, or suspected metabolic disease.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
Why does creatine supplementation not help individuals with SLC6A8 variants?
The transporter protein itself is faulty, so cells cannot take up creatine from the bloodstream even when dietary intake is increased. Supplementation raises blood creatine levels but does not address the underlying cellular uptake defect.
Can female carriers of SLC6A8 variants have symptoms?
Yes, some carrier females experience mild learning difficulties, speech delay, or behavioural features, though many remain asymptomatic. The variability depends on the pattern of X-chromosome inactivation across different tissues, particularly in the brain.
How is cerebral creatine deficiency diagnosed?
Diagnosis typically combines brain magnetic resonance spectroscopy showing reduced creatine peaks, biochemical testing of urine creatine-to-creatinine ratios, and genetic testing to identify pathogenic SLC6A8 variants. Definitive diagnosis requires molecular confirmation.
References
- van de Kamp JM, Mancini GM, Salomons GS. X-linked creatine transporter deficiency: clinical aspects and pathophysiology. Journal of inherited metabolic disease. 2014. PMID: 24789340
- Stockler-Ipsiroglu S, van Karnebeek CD. Cerebral creatine deficiencies: a group of treatable intellectual developmental disorders. Seminars in neurology. 2014. PMID: 25192512
- van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. Journal of medical genetics. 2013. PMID: 23644449
- Braissant O, Henry H, Béard E. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. Amino acids. 2011. PMID: 21390529
- Nasrallah F, Feki M, Kaabachi N. Creatine and creatine deficiency syndromes: biochemical and clinical aspects. Pediatric neurology. 2010. PMID: 20159424
- Béard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. Journal of neurochemistry. 2010. PMID: 20796169
- Rosenberg EH, Martínez Muñoz C, Betsalel OT. Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application. Human mutation. 2007. PMID: 17465020
- Clark AJ, Rosenberg EH, Almeida LS. X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. Human genetics. 2006. PMID: 16738945
- Sykut-Cegielska J, Gradowska W, Mercimek-Mahmutoglu S. Biochemical and clinical characteristics of creatine deficiency syndromes. Acta biochimica Polonica. 2004. PMID: 15625559
- Salomons GS, van Dooren SJ, Verhoeven NM. X-linked creatine transporter defect: an overview. Journal of inherited metabolic disease. 2003. PMID: 12889669